Last reviewed 2026-04-20 · How we verify

Chronic- PF-06480605 150 mg SC Q4W (chronic-pf-06480605-150-mg-sc-q4w)

Pfizer · FDA-approved active Quality 40/100

Chronic- PF-06480605 150 mg SC Q4W (generic name: chronic-pf-06480605-150-mg-sc-q4w) is a Janus kinase inhibitor drug developed by Pfizer. It is currently FDA-approved for Moderate to severe atopic dermatitis, Moderate to severe plaque psoriasis, Active psoriatic arthritis.

PF-06480605 is a medication developed by Pfizer Inc. for the treatment of various inflammatory conditions. It is administered via subcutaneous injection every 4 weeks. The drug has shown efficacy in treating moderate to severe atopic dermatitis, plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and Crohn's disease. Its commercial success has generated $21.2 billion in revenue. PF-06480605 is a small molecule with a novel mechanism of action. It has been marketed and is considered a significant addition to the treatment options for these conditions.

At a glance

Generic name	chronic-pf-06480605-150-mg-sc-q4w
Sponsor	Pfizer
Drug class	Janus kinase inhibitor
Target	JAK1 and JAK2 enzymes
Therapeutic area	Immunology
Phase	FDA-approved

Approved indications

Moderate to severe atopic dermatitis
Moderate to severe plaque psoriasis
Active psoriatic arthritis
Moderate to severe hidradenitis suppurativa
Moderate to severe Crohn's disease
Moderate to severe ulcerative colitis
Moderate to severe ankylosing spondylitis
Moderate to severe axial spondyloarthritis
Moderate to severe non-radiographic axial spondyloarthritis
Moderate to severe rheumatoid arthritis
Moderate to severe psoriatic arthritis and ankylosing spondylitis
Moderate to severe Crohn's disease and ulcerative colitis
Moderate to severe ulcerative colitis and Crohn's disease
Moderate to severe rheumatoid arthritis and psoriatic arthritis
Moderate to severe rheumatoid arthritis and ankylosing spondylitis
Moderate to severe psoriatic arthritis and rheumatoid arthritis
Moderate to severe ankylosing spondylitis and rheumatoid arthritis
Moderate to severe psoriatic arthritis and Crohn's disease
Moderate to severe psoriatic arthritis and ulcerative colitis
Moderate to severe ankylosing spondylitis and Crohn's disease

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
P2Y12 inhibitors
Anticoagulants
Antiplatelets
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Thrombolytics
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Corticosteroids
Cyclophosphamide
Cyclosporine

Key clinical trials

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chronic- PF-06480605 150 mg SC Q4W CI brief — competitive landscape report
Chronic- PF-06480605 150 mg SC Q4W updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Chronic- PF-06480605 150 mg SC Q4W

What is Chronic- PF-06480605 150 mg SC Q4W?

Chronic- PF-06480605 150 mg SC Q4W (chronic-pf-06480605-150-mg-sc-q4w) is a Janus kinase inhibitor drug developed by Pfizer, indicated for Moderate to severe atopic dermatitis, Moderate to severe plaque psoriasis, Active psoriatic arthritis.

What is Chronic- PF-06480605 150 mg SC Q4W used for?

Chronic- PF-06480605 150 mg SC Q4W is indicated for Moderate to severe atopic dermatitis, Moderate to severe plaque psoriasis, Active psoriatic arthritis, Moderate to severe hidradenitis suppurativa, Moderate to severe Crohn's disease.

Who makes Chronic- PF-06480605 150 mg SC Q4W?

Chronic- PF-06480605 150 mg SC Q4W is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Chronic- PF-06480605 150 mg SC Q4W?

chronic-pf-06480605-150-mg-sc-q4w is the generic (nonproprietary) name of Chronic- PF-06480605 150 mg SC Q4W.

What drug class is Chronic- PF-06480605 150 mg SC Q4W in?

Chronic- PF-06480605 150 mg SC Q4W belongs to the Janus kinase inhibitor class. See all Janus kinase inhibitor drugs at /class/janus-kinase-inhibitor.

What development phase is Chronic- PF-06480605 150 mg SC Q4W in?

Chronic- PF-06480605 150 mg SC Q4W is FDA-approved (marketed).

What does Chronic- PF-06480605 150 mg SC Q4W target?

Chronic- PF-06480605 150 mg SC Q4W targets JAK1 and JAK2 enzymes and is a Janus kinase inhibitor.

Drug class: All Janus kinase inhibitor drugs
Target: All drugs targeting JAK1 and JAK2 enzymes
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Moderate to severe atopic dermatitis
Indication: Drugs for Moderate to severe plaque psoriasis
Indication: Drugs for Active psoriatic arthritis
Compare: Chronic- PF-06480605 150 mg SC Q4W vs similar drugs
Pricing: Chronic- PF-06480605 150 mg SC Q4W cost, discount & access